CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 500 filers reported holding CRISPR THERAPEUTICS AG in Q2 2021. The put-call ratio across all filers is 1.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2021 | $971,000 | +77.2% | 6,000 | +33.3% | 0.25% | +74.3% |
Q1 2021 | $548,000 | +2.2% | 4,500 | +28.6% | 0.14% | +6.7% |
Q4 2020 | $536,000 | +46.0% | 3,500 | -30.0% | 0.14% | +11.6% |
Q2 2020 | $367,000 | -64.6% | 5,000 | -79.6% | 0.12% | -67.2% |
Q1 2020 | $1,038,000 | +240.3% | 24,472 | +389.4% | 0.37% | +355.6% |
Q4 2019 | $305,000 | – | 5,000 | – | 0.08% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 3,608,874 | $160,053,562,000 | 54.44% |
Abingworth LLP | 1,237,202 | $54,858,000 | 32.62% |
NEA Management Company, LLC | 2,090,678 | $92,722,000 | 4.00% |
New Leaf Venture Partners, L.L.C. | 444,708 | $19,723,000 | 3.59% |
EcoR1 Capital, LLC | 500,000 | $22,175,000 | 2.00% |
ARK Investment Management | 1,453,590 | $64,467,000 | 1.95% |
CLOUGH CAPITAL PARTNERS L P | 337,731 | $14,978,000 | 1.41% |
Casdin Capital, LLC | 220,000 | $9,757,000 | 1.19% |
Valiant Capital Management, L.P. | 271,700 | $12,050,000 | 1.07% |
Monashee Investment Management LLC | 110,000 | $4,879,000 | 1.03% |